Sort   by:  
 Page size 
UnknownCopy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis.
Not available
S-EPMC8831589 | biostudies-literature
UnknownMultiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.
Not available
S-EPMC10721318 | biostudies-literature
UnknownSequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Not available
S-EPMC4468690 | biostudies-literature
ProteomicsEstrogen Receptor Mutant Coregulator
Biotinylated 4xERE-containing DNA immobilized on streptavidin beads used to pulldown proteins recruited by unliganded WT ER-alpha versus Y537S, D538G, or ESR1-YAP1 fusion proteins from HeLa S3 human cell nuclear extracts.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-02-08 | MSV000080536 | MassIVE
UnknownLILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis.
Not available
S-EPMC10363120 | biostudies-literature
UnknownProteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.
Not available
S-EPMC6095836 | biostudies-literature
UnknownQuantum enhanced metrology based on flipping trajectory of cold Rydberg gases.
Not available
S-EPMC12858863 | biostudies-literature
UnknownFamitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Not available
S-EPMC9365373 | biostudies-literature
ProteomicsProteomic analysis for In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses
Proteomic analysis for In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses
ORGANISM(S): Mus Musculus 
2022-07-14 | PXD035315 |
UnknownSitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Not available
S-EPMC12831270 | biostudies-literature
Sort   by:  
 Page size